Advanced in Infantile Neutropenia

Dr. Todd M. Cooper

Pediatric Hematology Oncology
1600 7th Ave S, 
Birmingham, AL 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Advanced in Infantile Neutropenia
1600 7th Ave S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Todd Cooper is a Pediatric Hematologist Oncology provider in Birmingham, Alabama. Dr. Cooper is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Childhood Acute Myeloid Leukemia, Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Infantile Neutropenia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in AL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO

Locations

1600 7th Ave S, Birmingham, AL 35233

Additional Areas of Focus

Dr. Cooper has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure
Study Phase: Phase 1/Phase 2
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-08: a Phase 1 Study of SC-DARIC33 in Pediatric and Young Adults with Relapsed or Refractory CD33+ AML
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-08: a Phase 1 Study of SC-DARIC33 in Pediatric and Young Adults with Relapsed or Refractory CD33+ AML
Enrollment Status: Recruiting
Publish Date: November 19, 2024
Intervention Type: Biological
Study Drug: SC-DARIC33
Study Phase: Phase 1
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Genetic
Study Phase: Not Applicable
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: July 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cytarabine, Filgrastim, Fludarabine, Liposomal Daunorubicin, Liposomal Cytarabine
Study Phase: Phase 1/Phase 2
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 1
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Enrollment Status: Completed
Publish Date: June 24, 2022
Intervention Type: Drug
Study Drugs: Decitabine, Vorinostat, Filgrastim, Fludarabine, Cytarabine
Study Phase: Phase 1
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment Status: Terminated
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)
Enrollment Status: Withdrawn
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: January 29, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

85 Total Publications

Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.
Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2025
Similar Doctors
Experienced in Infantile Neutropenia
Dr. Girish Dhall
Pediatric Hematology Oncology
Experienced in Infantile Neutropenia
Dr. Girish Dhall
Pediatric Hematology Oncology
1600 7th Ave S, 
Birmingham, AL 
 (0.1 miles away)
205-638-9100
Languages Spoken:
English
See accepted insurances

Girish Dhall is a Pediatric Hematologist Oncology provider in Birmingham, Alabama. Dr. Dhall is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Medulloblastoma, Glioma, Embryonal Tumor with Multilayered Rosettes, and Diffuse Midline Glioma H3 K27M-Mutant.

Experienced in Infantile Neutropenia
Dr. Christina J. Bemrich
Pediatric Hematology Oncology
Experienced in Infantile Neutropenia
Dr. Christina J. Bemrich
Pediatric Hematology Oncology
1600 7th Ave S, 
Birmingham, AL 
 (0.1 miles away)
205-638-9285
Languages Spoken:
English
See accepted insurances

Christina Bemrich is a Pediatric Hematologist Oncology provider in Birmingham, Alabama. Dr. Bemrich is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Sickle Cell Disease, Febrile Neutropenia, Hemoglobinopathy, and Congenital Hemolytic Anemia.

Experienced in Infantile Neutropenia
Dr. Matthew A. Kutny
Pediatric Hematology Oncology
Experienced in Infantile Neutropenia
Dr. Matthew A. Kutny
Pediatric Hematology Oncology

University Of Alabama Health Services Foundation, PC

1600 7th Ave S, 
Birmingham, AL 
 (0.1 miles away)
205-975-9925
Languages Spoken:
English
See accepted insurances

Matthew Kutny is a Pediatric Hematologist Oncology provider in Birmingham, Alabama. Dr. Kutny is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Leukemia, Febrile Neutropenia, Acute Lymphoblastic Leukemia (ALL), Infantile Neutropenia, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cooper's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile